07-22-2010: Epigenomics AG reports that its licensee ARUP Laboratories, Salt Lake City, UT, U.S.A.,
today has announced the launched of a laboratory-developed test for the
blood-based detection of colorectal cancer. The test is based on
Epigenomics' proprietary Septin9 biomarker and DNA methylation
technologies non-exclusively licensed to ARUP in August 2009.
According to ARUP the independently developed and validated Septin9 test
identifies nine out of ten people with previously undetected colorectal
cancer, including those with early stage disease. ARUP states that the
test, which is now available to physicians and patients in the U.S., is
not meant to replace colonoscopy but primarily aims at patients who
cannot or will not undergo the established screening methods.
Contact / Request information
Request further information free of charge:
Epigenomics Biomarker Predicts Drug Resistance in Colorectal Cancer
Epigenomics AG announced the publication of a study authored by Professor Matthias Ebert at University of Heidelberg entitled “TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer” in The New England Journal of Medicine.In this study involving more than 200 patients in four independent coho ... more
Epigenomics AG: Noel Doheny Appointed as New CEO of US-Subsidiary Epigenomics Inc.
Epigenomics AG announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary Epigenomics Inc. in Seattle, WA, USA, reporting to Geert Nygaard, CEO of Epigenomics AG. Mr. Doheny will start in his new position in early May 2011. Mr. Doheny has 30+ years o ... more
Epigenomics AG and NextPharma Sign Global Manufacturing Deal for Colorectal Cancer Blood Test
Epigenomics AG and NextPharma Technologies announced that the companies have signed a global manufacturing contract for Epigenomics' Epi proColon product. Epi proColon, currently marketed in Europe, is the world's first in-vitro diagnostic test for the detection of colorectal cancer in a s ... more
Epigenomics AG reports that its licensee ARUP Laboratories, Salt Lake City, UT, U.S.A., today has announced the launched of a laboratory-developed test for the blood-based detection of colorectal cancer. The test is based on Epigenomics' proprietary Septin9 biomarker and DNA methylation tec ... more
Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories
Epigenomics AG announced that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin 9 (mSEPT9) with Salt Lake City, Utah, U.S. based ARUP Laboratories, Inc. (ARUP). Under the agreement, ARUP has obtained rights to use the mSEPT9 biomarker to deve ... more
About analytica-world.com
analytica-world.com is the industry portal of the international trade fair analytica, which is organized by Messe München. It features useful information about markets, trends and innovations. It is operated by CHEMIE.DE, one of analytica's official sales partners.
Advertising at analytica-world.com
Our advertising formats support you in getting your message across to a clearly defined target audience.
The global network of analytica trade fairs:
